Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Conditions
- Non-small Cell Lung Cancer Stage IIIC
- Non-small Cell Lung Cancer Stage IV
- Non Small Cell Lung Cancer
- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Unresectable
Interventions
- DRUG: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.
- DRUG: Standard of Care
Sponsor
University of California, Davis
Collaborators